.jpeg)
2026-08-17 07:50:41
Bristol Myers Squibb announced FDA approval of Zenbexus (iberdomide) in combination with the ZDd regimen for adults with multiple myeloma who have received at least one prior line of therapy — the first approved CELMoD therapy.
2026-08-17 06:53:57
While delivering its intended therapeutic benefits, elamipretide hydrochloride may induce adverse reactions predominantly manifesting as injection site responses and hypersensitivity risks. This article systematically outlines its safety profile, contraindications in special populations, and cold-chain storage requirements.
2026-08-17 06:41:29
A detailed overview of adverse reactions associated with dutasteride soft capsules for benign prostatic hyperplasia, covering sexual dysfunction, breast-related events, serious risks, and evidence-based mitigation approaches.
2026-08-17 06:24:52
Oral semaglutide tablets, developed by Novo Nordisk, are the world's first oral GLP-1 receptor agonist, indicated for glycemic control in adults with type 2 diabetes and for reducing major adverse cardiovascular events in high-risk patients.
2026-08-17 06:12:53
Sotorasib (brand name: Lumakras), developed by Amgen, is the world's first KRAS G12C inhibitor approved by the U.S. FDA in May 2021. It is indicated for adults with KRAS G12C-mutant advanced non-small cell lung cancer and metastatic colorectal cancer.
2026-08-14 03:20:41
This article systematically interprets Osimertinib, a core therapeutic drug for EGFR mutation-positive non-small cell lung cancer, covering pharmacological efficacy, common and serious adverse reactions, indications, usage and dosage, drug interactions and key points for special populations, providing a comprehensive reference for standardized clinical medication.
2026-08-14 02:50:16
Sotorasib (brand name Lumakras) is the world's first approved targeted drug for KRAS G12C mutations, used in precision treatment of non-small cell lung cancer and colorectal cancer. This article explains its efficacy limits, approved indications, mechanism of action, and safety considerations to help patients set realistic treatment expectations.
2026-08-13 04:17:25
Trametinib is a highly selective MEK1/2 inhibitor used in BRAF V600-mutant melanoma, NSCLC, low-grade glioma, and other solid tumors. This article details refrigeration requirements, fasting dosing protocols, missed-dose management, eligible patient populations, and special-population considerations to support safe and standardized treatment.
2026-08-13 04:02:58
Asciminib (brand name SCEMBLIX) is the first STAMP-class targeted therapy for chronic myeloid leukemia. This article clarifies nomenclature consistency, strict fasting requirements, missed-dose protocols, and safety monitoring essentials to help patients avoid medication errors and optimize therapeutic outcomes.
2026-08-13 03:58:16
Belzutifan (brand name Welireg) is the first oral hypoxia-inducible factor-2α (HIF-2α) inhibitor, holding a unique position in managing VHL disease-associated tumors and clear cell renal cell carcinoma. This article systematically reviews its phased treatment strategy, survival outcomes, efficacy-modifying factors, adverse event management, and special-population considerations.
2026-08-13 03:52:54
Cabergoline is a long-acting dopamine receptor agonist used primarily for hyperprolactinemia. This guide systematically covers contraindicated populations, standard dosing regimens, cost estimates, long-term cardiac monitoring requirements, and overseas version selection to help patients plan safe and sustainable treatment.
2026-08-12 04:21:50
Pemigatinib and Anlotinib are both anti-tumor targeted agents, yet they differ fundamentally in mechanism, target specificity, and applicable cancer types. This article provides a systematic comparison across molecular mechanisms, indications, precision, adverse effects, and treatment selection to guide informed clinical decisions.
